Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER vs AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Intravenous amino acids and dextrose provide essential nitrogen and calories for protein synthesis and energy metabolism. Electrolytes maintain osmotic balance and cellular function. Calcium is critical for neuromuscular transmission and bone health.
Provides essential amino acids and histidine for protein synthesis in patients unable to tolerate oral or enteral nutrition, supporting nitrogen balance and tissue repair. The amino acids are utilized for anabolic processes and metabolic pathways.
Total parenteral nutrition in patients who require combined amino acid, dextrose, and electrolyte supplementation,Peripheral parenteral nutrition when central access is not feasible
Treatment of uremic patients undergoing dialysis who require essential amino acid supplementation,Nutritional support in patients with renal insufficiency or failure where nonessential nitrogen sources are contraindicated
Intravenous infusion: Adult dose is based on protein and caloric requirements. Typical dose: 1-2 L/day of this 4.25% amino acid, 20% dextrose solution, providing approximately 4.25 g amino acid/100 m L and 680 kcal/L. Infusion rate should be adjusted to avoid hyperglycemia, usually starting at 25-50 m L/hr and increasing gradually.
Intravenous infusion: 500 m L of 5.2% solution (26 g amino acids) over 8-12 hours daily, providing 0.8-1.2 g/kg/day of amino acids depending on metabolic needs.
Not applicable as a single entity; components have distinct half-lives: dextrose ~1.5-2 hours (glucose); amino acids ~5-10 minutes; electrolytes vary (e.g., calcium ~2-3 hours). Clinical context: continuous infusion achieves steady state.
Approximately 2-4 hours for most essential amino acids; clinical context: rapid clearance necessitates continuous infusion for stable plasma levels.
Amino acids undergo hepatic metabolism and renal excretion of nitrogenous wastes; dextrose is metabolized via glycolysis and oxidative phosphorylation; electrolytes are excreted renally.
Amino acids are metabolized via transamination, deamination, and incorporation into proteins. Hepatic and renal pathways involved in nitrogen disposal and urea cycle.
The amino acids and electrolytes are metabolized or utilized; dextrose is oxidized to CO2 and water. Renal excretion of nitrogen is ~60-80% as urea, with minor losses in feces (5-10%) and skin (2-5%). Electrolytes are excreted primarily renally.
Renal: >95% as amino acids and metabolites; negligible biliary/fecal.
Minimal for most components (<10% for amino acids and electrolytes); calcium ~40% bound to albumin.
Minimal (<10%) for most amino acids; not significantly protein-bound.
Not applicable as a mixture; individual components vary: dextrose Vd ~0.2 L/kg, electrolytes distribute in total body water (e.g., sodium 0.6 L/kg).
Approximately 0.2-0.4 L/kg total body water; reflects distribution primarily into extracellular fluid.
Intravenous: 100%.
Intravenous: 100%.
Contraindicated in patients with severe renal impairment (e GFR < 30 m L/min/1.73 m²) unless on dialysis. In moderate impairment (e GFR 30-59 m L/min/1.73 m²), reduce dose by 50% and monitor electrolytes.
For GFR < 30 m L/min: reduce dose to 0.5-0.8 g/kg/day; for GFR < 15 m L/min: 0.3-0.5 g/kg/day; avoid if severe untreated uremia.
Contraindicated in patients with severe hepatic encephalopathy. In Child-Pugh Class B or C, use with caution; reduce dose by 50% and monitor ammonia levels.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25-50%; Child-Pugh C: contraindicated due to risk of hepatic encephalopathy.
Dose based on weight (kg): 2-3 g amino acids/kg/day and 10-20 g dextrose/kg/day. Typical infusion rate: 0.1-0.2 m L/kg/hr initially, titrated to clinical response. Not recommended for neonates due to high dextrose concentration.
Infants and children: 1-2 g/kg/day as continuous infusion; neonates: 0.5-1 g/kg/day, titrated to metabolic response.
No specific dose adjustment; use lower initial infusion rates (25-50 m L/hr) due to reduced renal and hepatic function. Monitor glucose and electrolytes closely.
Start at 0.6-0.8 g/kg/day; monitor renal function and protein tolerance; adjust for comorbidities like renal impairment or heart failure.
Not for use in patients with known hypersensitivity to any component; risk of metabolic acidosis, hyperglycemia, or electrolyte imbalances if not monitored appropriately.
Not for intravenous infusion. For oral or enteral use only. Do not administer parenterally.
Monitor for signs of infection, hyperglycemia, electrolyte disturbances, and fluid overload. Use with caution in patients with renal impairment, hepatic disease, or diabetes. Do not administer simultaneously with blood products through same IV line.
Monitor serum electrolytes, BUN, and ammonia levels; risk of hyperammonemia in hepatic impairment,Use with caution in patients with metabolic acidosis or fluid overload,May cause gastrointestinal intolerance; adjust rate of administration
Known hypersensitivity to any ingredient, severe hyperglycemia, hyperkalemia, hypercalcemia, anuria, or inborn errors of amino acid metabolism.
Hypersensitivity to any component,Phenylketonuria (contains phenylalanine),Severe hepatic failure with hyperammonemia
No oral food interactions as this is an intravenous formulation. However, if transitioning to oral intake, monitor for refeeding syndrome and adjust accordingly. Avoid simultaneous administration of medications or other additives unless compatibility confirmed.
No specific food interactions. Patients should follow prescribed dietary protein restrictions if indicated (e.g., in hepatic encephalopathy). Avoid alcohol as it may worsen liver function.
CLINIMIX E 4.25/20 is a parenteral nutrition solution containing amino acids, electrolytes, and dextrose. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted with this combination product. Dextrose at high doses may cause fetal hyperglycemia and hyperinsulinemia, potentially leading to neonatal hypoglycemia. Electrolyte imbalances (e.g., calcium) can affect fetal development. Use only if clearly needed and monitor maternal glucose and electrolytes closely. First trimester risks are theoretical; second and third trimester risks include fetal hyperglycemia and electrolyte disturbances.
Amino acid solutions like Aminess 5.2% are essential for fetal development. No teratogenic effects reported; however, use only if clearly needed as maternal nutritional status directly impacts fetal outcomes.
No data on excretion of CLINIMIX E components in breast milk. Dextrose and amino acids are normal milk constituents. Calcium and other electrolytes are present in milk, but parenteral administration may increase levels. M/P ratio not available. Caution: potential for maternal hyperglycemia or electrolyte imbalances affecting milk composition. Use only if clearly needed, and monitor infant for hypoglycemia or electrolyte disturbances.
No data available on milk concentrations. Essential amino acids are normal components of breast milk. Use with caution; benefits likely outweigh risks in malnourished mothers.
Pregnancy increases plasma volume and renal blood flow, potentially lowering serum electrolyte concentrations; adjust electrolyte doses based on frequent monitoring. Glucose tolerance decreases; may require reduced dextrose infusion rate or insulin to maintain euglycemia. Protein requirements increase; amino acid dose may need adjustment. Total fluid volume may need adjustment due to expanded intravascular volume. No standard dose recommendations; individualize based on metabolic status.
Pregnancy increases plasma volume and glomerular filtration rate, potentially altering pharmacokinetics. Monitor clinical response and consider dose adjustments based on metabolic demands; no specific dose adjustment guidelines available.
This total parenteral nutrition formulation provides 4.25% amino acids and 20% dextrose with electrolytes and calcium. Do not add additional calcium or phosphate without compatibility check to avoid precipitation. Use a dedicated line with an inline filter (1.2 micron for lipid-containing, 0.22 micron for non-lipid). Monitor serum glucose, electrolytes, renal and hepatic function. Adjust rate gradually to prevent hyperglycemia or rebound hypoglycemia. Note sulfite-free for sulfite-sensitive patients.
Monitor serum ammonia levels in patients with hepatic impairment as essential amino acids may exacerbate hyperammonemia. Use with caution in fluid-restricted patients due to high volume load. Ensure adequate non-protein calories to promote protein synthesis and prevent amino acid catabolism. Do not administer simultaneously with blood products via same IV line.
This solution is given intravenously to provide nutrition when you cannot eat.,Report any signs of infection at the IV site (redness, swelling, pain) or fever.,You will have regular blood tests to check your sugar, electrolyte, and organ function.,Do not stop or change the infusion rate yourself; it must be adjusted gradually.,Notify your nurse if you experience headache, nausea, sweating, or rapid heartbeat, which may indicate low blood sugar.
This solution provides essential amino acids to support protein synthesis when you cannot eat enough protein.,It is given intravenously; report any burning, pain, or swelling at the IV site.,Your blood may be monitored for ammonia and electrolyte levels during treatment.,Inform your healthcare provider if you have liver disease, diabetes, or fluid restrictions.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER vs AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE, answered by our medical review team.
CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER is a Parenteral Nutrition Solution that works by Intravenous amino acids and dextrose provide essential nitrogen and calories for protein synthesis and energy metabolism. Electrolytes maintain osmotic balance and cellular function. Calcium is critical for neuromuscular transmission and bone health.. AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE is a Parenteral Nutrition Solution that works by Provides essential amino acids and histidine for protein synthesis in patients unable to tolerate oral or enteral nutrition, supporting nitrogen balance and tissue repair. The amino acids are utilized for anabolic processes and metabolic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER and AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE depend on the specific clinical indication. These are both Parenteral Nutrition Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER is: Intravenous infusion: Adult dose is based on protein and caloric requirements. Typical dose: 1-2 L/day of this 4.25% amino acid, 20% dextrose solution, providing approximately 4.25 g amino acid/100 m L and 680 kcal/L. Infusion rate should be adjusted to avoid hyperglycemia, usually starting at 25-50 m L/hr and increasing gradually.. The standard adult dose of AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE is: Intravenous infusion: 500 m L of 5.2% solution (26 g amino acids) over 8-12 hours daily, providing 0.8-1.2 g/kg/day of amino acids depending on metabolic needs.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER and AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER is classified as Category C. CLINIMIX E 4.25/20 is a parenteral nutrition solution containing amino acids, electrolytes, and dextrose. There are no adequate and well-controlled studies in pregnant women. Anima. AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE is classified as Category C. Amino acid solutions like Aminess 5.2% are essential for fetal development. No teratogenic effects reported; however, use only if clearly needed as maternal nutritional status dire. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.